Literature DB >> 10543369

Infectious complications in chronic lymphocytic leukaemia.

E Morra1, A Nosari, M Montillo.   

Abstract

Infections are the major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). Predisposition to infection in CLL is mediated through various abnormalities including both the immune defects inherent in the primary disease (impairment in humoral and cellular immunity) and in the further immunosuppression related to the management of CLL. Hypogammaglobulinemia is probably the most important immune defect in terms of risk of severe bacterial infections, its frequency and severity progressing with the duration of the disease. Newer antineoplastic agents such as purine analogues, especially when used in previously treated patients, may be associated with a new spectrum of pathogens (Listeria monocytogenes, Pneumocystis carinii, cytomegalovirus, herpes simplex virus, and mycobacteria) involving T-cell dysfunction. In this review we focus on the clinical characteristics of infections in CLL and on the risk factors involved in the pathogenesis of this complication. Furthermore, we describe the evolving patterns of infections associated with purine analogues and discuss the currently accepted approaches to prophylaxis and treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543369     DOI: 10.1007/s00282-999-0145-0

Source DB:  PubMed          Journal:  Hematol Cell Ther        ISSN: 1269-3286


  6 in total

Review 1.  A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Authors:  S Lachance; A L Christofides; J K Lee; L H Sehn; B C Ritchie; C Shustik; D A Stewart; C L Toze; E Haddad; D C Vinh
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

Review 2.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 3.  Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.

Authors:  Constantin A Dasanu; Doru T Alexandrescu
Journal:  MedGenMed       Date:  2007-11-15

Review 4.  Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.

Authors:  Ben Kennedy; Peter Hillmen
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

5.  Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.

Authors:  S Shahzad Mustafa; Saad Jamshed; Karthik Vadamalai; Allison Ramsey
Journal:  PLoS One       Date:  2021-10-15       Impact factor: 3.240

Review 6.  Cytomegalovirus in Haematological Tumours.

Authors:  Sara Alonso-Álvarez; Enrique Colado; Marco A Moro-García; Rebeca Alonso-Arias
Journal:  Front Immunol       Date:  2021-10-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.